Split History
NAVB split history picture
Navidea Biopharmaceuticals (NAVB) has 1 split in our NAVB split history database. The split for NAVB took place on April 26, 2019. This was a 1 for 20 reverse split, meaning for each 20 shares of NAVB owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 50 share position following the split.

When a company such as Navidea Biopharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the NAVB split history from start to finish, an original position size of 1000 shares would have turned into 50 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Navidea Biopharmaceuticals shares, starting with a $10,000 purchase of NAVB, presented on a split-history-adjusted basis factoring in the complete NAVB split history. NAVB split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 12/10/2012
End date: 12/06/2022
Start price/share: $55.40
End price/share: $0.25
Dividends collected/share: $0.00
Total return: -99.55%
Average Annual Total Return: -41.75%
Starting investment: $10,000.00
Ending investment: $45.11
Years: 9.99
Navidea Biopharmaceuticals is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Co. is developing multiple precision-targeted products based on its Manocept™ platform to improve patient care by identifying the sites and pathways of undetected disease and enable diagnostic, clinical decision-making and targeted treatment. Co.'s business is focused on two primary types of drug products: diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and therapeutic development programs, including therapeutic applications of its Manocept platform. According to our NAVB split history records, Navidea Biopharmaceuticals has had 1 split.
Date Ratio
04/26/20191 for 20
NAVB is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

NBS Split History
NBY Split History
NEOG Split History
NERV Split History
NNVC Split History
NOVN Split History
NRCIB Split History
NSPH Split History
NSPR Split History
NURO Split History

Email EnvelopeFree NAVB Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Checkpoint Therapeutics, Inc. (CKPT)
UpHealth, Inc. (UPH)
MediWound Ltd. (MDWD)
Eloxx Pharmaceuticals, Inc. (ELOX)
Baudax Bio, Inc. (BXRX)
Petros Pharmaceuticals, Inc. (PTPI)
Tuesday Morning Corporation (TUEM)
DURECT Corporation (DRRX)
CNS Pharmaceuticals, Inc. (CNSP)
Astrotech Corporation (ASTC)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

NAVB Insider Buying

NAVB Split History | www.SplitHistory.com | Copyright © 2013 - 2022, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.